SLC5A2 and diabetes mellitus: With regard to kidney disease in people with diabetes the Canagliflozin and Kidney Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) was the first study of an SGLT‐2 inhibitor to have kidney outcomes in its primary composite endpoint.77